State
of New
York
|
1-10113
|
11-0853640
|
(State
of Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification Number)
|
(i) |
the
extension of the maturity date of the Bridge Loans from March 31,
2007 to
September 30, 2007;
|
(ii) |
the
continued satisfaction of interest payments in the Registrant’s common
stock based upon the average of the closing bid and asked prices
of the
common stock for the five (5) trading days immediately preceding
the
interest payment date;
|
(iii) |
the
commitment for additional bridge funding to be provided by the VC
Lenders
in the principal amount of up to $600,000 million (after giving effect
to
the Bridge Loan of $600,000 made by the VC Lenders on March
30, 2007
and described in Item 8.01 below); and
|
(iv) |
the
right of the bridge lenders to convert the Bridge Loans (including
the
additional bridge loans to be advanced under subsection (iii) above)
(the
“Bridge Loan Financing”), into the Registrant’s common stock upon the
completion of a third-party equity financing providing gross proceeds
to
the Registrant in the aggregate amount of at least $5 million (a
“Third
Party Equity Financing”), a Change of Control Transaction or upon the
maturity date of the Bridge Loan Financing (each a “Triggering Event”).
Upon the occurrence of a Triggering Event, the bridge
lenders may convert the $2.00 million of Bridge Loans secured from
November 2006 through February 2007 (the “November 2006 Bridge Loans”) and
the Bridge Loans secured March
30, 2007
and any future Bridge Loans into the Registrant’s common stock at a
conversion price equal to (A)
in the case of the completion of a Third Party Equity Financing,
the
lesser of (i) the average price of the securities sold by the Registrant
in such Third Party Equity Financing, (ii) 80% of the average closing
bid
and asked prices of the Registrant’s common stock for the twenty trading
days immediately preceding the public announcement of the Third Party
Equity Financing, and (iii) $0.46 per share ($0.44, in the case of
the
November 2006 Bridge Loans) and (B) in the case of a Change of Control
Transaction or upon the maturity date of the Bridge Loan Financing,
the
lesser of (i) $0.46 per share ($0.44, in the case of the November
2006
Bridge Loans) and (ii) 80% of the average closing bid and asked prices
of
the Registrant’s common stock for the twenty trading days immediately
preceding the public announcement of the Change of Control Transaction
or
the maturity date, as applicable, but in no event in the case of
clauses
(A) and (B), less than $0.21 per share. In addition, upon a Triggering
Event, the bridge lenders may convert (i) $2.55 million of Bridge
Loan
Financing into the Company's common stock at a conversion price of
$0.20
per share, (ii) $2.3 million of Bridge Loan Financing at a conversion
price of $0.225 per share and (iii) $1.894 million of bridge loan
financing at a conversion price of $0.25 per share, and in addition
in the
case of clauses (i)-(iii) of this sentence in a Third Party Equity
Financing, on the same terms as provided in such Third-Party Equity
Financing (but not less than $0.21 per share).
|
Exhibit
Number
|
Description
|
10.1
|
Omnibus
Amendment and Consent effective as of March
30, 2007
between the Registrant and various lenders.
|
99.1
|
Press
Release dated April 2, 2007 Announcing Receipt of Bridge Funding
|
ACURA PHARMACEUTICALS, INC. | ||
|
|
|
By: | /s/ Peter A. Clemens | |
Peter A. Clemens |
||
Senior Vice President & Chief Financial Officer |
Exhibit
Number
|
Description
|
10.1
|
Omnibus
Amendment and Consent effective as of March
30, 2007
between the Registrant and various lenders.
|
99.1
|
Press
Release dated April 2, 2007 Announcing Receipt of Bridge Funding
|